Does it matter?

One day someone will have to explain to us how a company that once dominated a market only to screw it up because of their own arrogance should be given the benefit of the doubt. This is basically what Medtronic is asking investors to do when it comes to their still struggling diabetes unit. They want to be given yet another chance as this is not the first not even the second time this unit is in the midst of a turnaround. Keep in mind we’ve been covering MiniMed since we started writing Diabetic Investor.

Looking at the . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

© 2005 - 2021 Diabetic Investor, Inc., all rights reserved. Unless expressly permitted under your written license agreement, you are not authorized to forward or to otherwise copy our newsletter, or any portion thereof, by electronic means or otherwise. 17 U.S.C. §504 provides for statutory damages of up to $150,000 per infringement of a copyright and additional damages.